Glancy Prongay & Murray LLP Announces Investigation on Behalf of Reliq Health Technologies Inc. Investors
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Reliq Health Technologies Inc. (“Reliq” or the
“Company”) (TSXV:
RHT, OTCQB:
RQHTF) investors concerning the Company and its officers’ possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click
here to participate.
The investigation concerns whether Reliq misled investors regarding future revenues and customer reimbursements. On October
16, 2018, Reliq announces that it has decided to restate certain financial information reported for the quarter ended March 31,
2018. On this news, shares of Reliq fell significantly during intraday trading, thereby injuring investors.
Follow us for updates on Twitter:
twitter.com/GPM_LLP.
If you purchased Reliq Therapeutics securities, have information or would like to learn more about these claims, or have any
questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy,
Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by
email to shareholders@glancylaw.com, or visit our website at
www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares
purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Glancy Prongay & Murray LLP, Los Angeles/New York
Lesley Portnoy, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181017005787/en/